ATHERSYS, INC. (NASDAQ:ATHX) Files An 8-K Other Events
Item8.01.
| Other Events. |
Athersys, Inc. (the Company) is filing
herewith the following exhibit to its Registration Statement on
Form S-3 (Registration No.333-194538):
1. Underwriting Agreement, dated as of January27, 2017, between
the Company and William Blair Company, L.L.C., as representative
of the underwriters named therein.
| Item9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit Number |
Description |
|
| 1.1 |
Underwriting Agreement, dated as of January 27, 2017, between the Company and William Blair Company, L.L.C., as representative of the underwriters named therein. |
About ATHERSYS, INC. (NASDAQ:ATHX)
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI. ATHERSYS, INC. (NASDAQ:ATHX) Recent Trading Information
ATHERSYS, INC. (NASDAQ:ATHX) closed its last trading session up +0.07 at 1.16 with 1,190,263 shares trading hands.